Locations:

Tag: disease-modifying therapy

medication vials, syringes, tablets and capsules on a tabletop

April 14, 2025/Neurosciences/Multiple Sclerosis

Early Intensive or Escalation Therapy for Relapsing-Remitting Multiple Sclerosis?

Extension of DELIVER-MS trial will clarify long-term clinical effects of dueling treatment philosophies

22-NEU-3087358_pediatric-multiple-sclerosis_650x450

September 27, 2022/Neurosciences/Pediatrics

Making Pediatrics More of a Priority in Multiple Sclerosis Treatment Trials

New review makes the case for earlier pediatric enrollment and other changes

March 18, 2020/COVID-19

How to Counsel MS Patients on Disease-Modifying Therapy About COVID-19

In general, interrupting therapy is not advised, and patients should remain in contact with their provider teams

19-NEU-6534-Cohen-stem-cells-for-MS_Hero_650x450

January 17, 2020/Cancer

New BEAT-MS Trial Stages Direct Comparison of Stem Cells and Biologics for Relapsing MS

Knocking out, then restoring, the immune system holds great promise

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

September 19, 2019/Neurosciences/News & Insights

AAN Updates Its Guideline on Vaccines in Multiple Sclerosis: What Providers Need to Know

Recommendations revisited in wake of a surge in disease-modifying therapies

April 23, 2018/Neurosciences/Insight & Perspectives

Generics and Biosimilars in Multiple Sclerosis: Navigating a New Therapy Landscape

What neurologists need to know about this emerging development

BackPage 1 of 1Next